We investigated the utility of three-dimensional (3D) spheroid cultures of human hepatocytes in discovering drug metabolites. Metabolites of acetaminophen, diclofenac, lamotrigine, midazolam, propranolol and salbutamol were analyzed by liquid chromatography-tandem mass spectrometry (LC/MS/MS) to measure enzyme activities in this system cultured for 2 and 7 days. Sequential metabolic reactions by Phase I and then Phase II enzymes were found in diclofenac [CYP2C9 and UDP-glucuronyltransferases (UGTs)], midazolam (CYP3A4 and UGTs) and propranolol (CYP1A2/2D6 and UGTs). Moreover, lamotrigine and salbutamol were metabolized to lamotrigine-N-glucuronide and salbutamol 4-O-sulfate, respectively. These metabolites, which are human specific, could be observed in clinical studies, but not in conventional hepatic culture systems as in previous reports. Acetaminophen was metabolized to glucuronide and sulfate conjugates, and N-acetyl-p-benzo-quinoneimine (NAPQI) and its metabolites were not observed. In addition, mRNA of drug-metabolism enzymes [CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, UGT1A1, UGT2B7, sulfotransferase 1A1 (SULT1A1) and glutathione S-transferase pi 1 (GSTP1)], which were measured by qRT-PCR, were expressed in the human hepatocyte spheroids. In conclusion, these results suggest that human hepatocyte spheroids are useful in discovering drug metabolites.
Introduction
Biotransformation of drugs is one of the most important factors affecting pharmacokinetic properties, and hence the overall therapeutic and toxicity profiles. Drug metabolisms are often assessed by human hepatic microsomes, which have various drug enzymes. However, assays using human hepatocytes are recommended for predicting metabolites in humans, because microsomes lack cytosol enzymes and several cofactors for drug metabolism. The typical use of human hepatocytes in metabolite assays involves incubation of new compounds with suspensions of fresh or cryopreserved cells, or conventional two-dimensional (2D) cells. However, studies using the fresh or cryopreserved cells are limited by the incubation period, as metabolic capacity declines within a few hours. In many cases, the metabolite profiles of compounds in such studies do not reflect those in vivo. Although 2D cultures of primary human hepatocytes are frequently used for biotransformation of drugs, it is difficult to maintain the hepatic physiological function in long-term cultures. For example, changes in the expression levels of various drug-metabolism enzymes have been observed. 1, 2) Moreover, culturing hepatocytes in conventional 2D plates would cause morphological alterations and loss of cell polarity and specific hepatic functions. 3, 4) Therefore, there is a need for long-term stability of functioning hepatocytes in drug metabolism and pharmacokinetic (DMPK) studies.
Three-dimensional (3D) cultures of human hepatocytes are considered to be a promising DMPK model in vitro.
5) The purpose of this study is to prove whether assays using human hepatocyte spheroids reflect human metabolic profiles. Therefore, we identically and qualitatively compared the metabolites from the tested drugs in this assay with reported metabolites in clinical studies. Moreover, we performed comprehensive mRNA expression of metabolism enzymes in 3D cultures of primary hepatocytes.
Methods
Chemicals: Acetaminophen, diclofenac, lamotrigine, midazolam, salbutamol, propranolol and dextrophan were purchased from Sigma Aldrich (St. Louis, MO). Cryopreserved human hepatocytes were purchased from Charles River (Lot No. Hu8110, Tokyo, Japan). William's Medium E, Cryopreserved Hepatocytes Recovery Medium (CHRM µ ) and Hepatocyte Plating Supplement Pack (CM3000) were purchased from Invitrogen (Durham, NC). A 3D culture system, Cell-able™ 96-well and 24-well plates, and RM101 medium were purchased from Transparent (Chiba, Japan). 3T3-Swiss Albino cells were purchased from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). All other reagents and solvents were commercial products of analytical grade.
Three-dimensional culture of human hepatocytes and metabolic assays: Feeder cells (3T3-Swiss Albino cells) were cultured in DMEM (Wako Pure Chemical Industries, Osaka, Japan) with penicillin (100 µg/mL, Nacalai Tesque, Kyoto, Japan), streptomycin (100 µg/mL, Wako Pure Chemical Industries) and 10% fetal bovine serum (Invitrogen). The cells were cultured in a humidified atmosphere containing 5% CO 2 at 37°C. Feeder cells were plated at a density of 8 © 10 3 cells/well on 96-well format Cell-able™. After 4 days, cryopreserved human hepatocytes were seeded. Briefly, they were stored in liquid nitrogen until use, and immediately immersed in water pre-warmed to 37°C. After dissolution of the hepatocytes, they were decanted into CHRM µ and centrifuged at 100 © g for 10 min. The hepatocytes were re-suspended in William's Medium E containing CM3000. The viability of the hepatocytes was assessed by trypan blue exclusion, and suspensions with viability of over 90% were used. They were seeded at a density of 2.0 © 10 4 cells/well on the Cell-able™ and maintained using RM101 medium (containing 1% FBS, Transparent) for spheroid-formation periods of 2, 7, 14 or 21 days before assays. In metabolism assays, the hepatocyte spheroids were cultured with the culture medium (RM101) containing test compounds for 2 or 7 days.
LC/MS/MS analysis:
The amount of unchanged compound remaining was determined using a Xevo™ TQ MS (Waters, MA) tandem quadrupole mass spectrometer coupled with an ACQUITY UPLC µ system (Waters) as previously described. 6) The mass numbers of the molecular and product ions for each compound were as follows: acetaminophen (152.0 ¼ 110.1), diclofenac (296.0 ¼ 214.6), lamotrigine (256.0 ¼ 109.0), midazolam (326.1 ¼ 128.9), salbutamol (240.1 ¼ 148.0) and propranolol (260.1 ¼ 116.0). The metabolites were identified by comparing the retention times and molecular weights of the standard compounds. When corresponding metabolites were not commercially available, they were estimated using these calculated molecular weights and ion fragment patterns. The amounts of metabolites were determined by relative ratio to the ion peak areas of dextrorphan, an internal standard (IS).
mRNA expression assay: The feeder cells were plated at a density of 4.0 © 10 4 cells/well on 24-well format Cell-able™. After 4 days, cryopreserved human hepatocytes were seeded at a density of 1.0 © 10 5 cells/well on the Cell-able™. The total RNA was extracted from the hepatocytes cultured on the Cell-able™ after 2 and 7 days. The mRNA expression of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, UGT1A1, UGT2B7, SULT1A1 and GSTP1 was measured by quantitative RT-PCR (qRT-PCR), using THUNDERBIRD SYBR qPCR Mix (TOYOBO, Osaka, Japan). Since hypoxanthine guaninephosphoribosyl-transferase 1 (HPRT1) mRNA exhibited stable expression in human hepatocytes, 7) the mRNA expression of target genes was normalized to HPRT1, and was calculated relative to that of the cryopreserved hepatocytes (set to 100%) using the 2-¦¦ threshold cycles (Ct) method.
8) The gene-specific primer sequences are listed in Table 1 .
Results

Substrate depletion in the human hepatocyte spheroids:
The tested compounds (acetaminophen, diclofenac, lamotrigine, midazolam, salbutamol and propranolol) were incubated in hepatocyte spheroids for 2 ( Fig. 1A ) and 7 days (Fig. 1B) after spheroid-formation periods of 2, 7, 14 and 21 days. The metabolic activity of hepatocyte spheroids increased for up to 7 days during the culture periods. However, the metabolic activities for spheroidformation periods of 14 and 21 days decreased compared with those for 2 and 7 days. Therefore, the period of spheroid formation was set at 2 days for subsequent examinations.
Biotransformation of drugs in the human hepatocyte spheroids: The biotransformation assays of drugs were measured after incubation with the hepatocyte spheroids for 2 and 7 days ( Table 2) .
Diclofenac, a substrate of CYP2C9, was converted to hydroxyl diclofenac, diclofenac acyl glucuronide and 4A-hydroxy diclofenac acylglucuronide at 2 days. In addition, 4A,5-dihydroxy diclofenac was observed at 7 days ( Table 2 ; see Supplemental Fig. 1A ). The production of N,5-dihydroxy diclofenac, known as a hepatotoxic metabolite of diclofenac, 9) was not observed. Midazolam, a substrate of CYP3A4, was converted to 1A-hydroxy midazolam, midazolam N-glucuronide, 1A-hydroxymidazolam O-glucuronide, 1A-hydroxy midazolam N-glucuronide, 4-hydroxy midazolam and 4-hydroxy midazolam N-glucuronide at 2 days ( Table 2 ; see Supplemental Fig. 1B) . At 7 days of incubation, 1A-hydroxymidazolam and 4-hydroxymidazolam were not observed, suggesting that these metabolites were converted to their glucuronide form. Propranolol, a substrate of CYP1A1 and CYP2D6, was converted to hydroxyl propranolol, propranolol Oglucuronide and hydroxyl propranolol glucuronide ( Table 2 ; see Supplemental Fig. 1C ).
Lamotrigine and salbutamol were converted to lamotrigine Nglucuronide and salbutamol 4-O-sulfate, respectively ( Table 2) .
During the 2-and 7-day incubation periods, acetaminophen was conjugated with sulfate and glucuronide ( Table 2 ; see Supplemental Fig. 1D) . N-Acetyl-p-benzo-quinoneimine (NAPQI), which is a toxic metabolite of acetaminophen, and its metabolites such as glutathione conjugate were not observed.
mRNA expression of drug-metabolizing enzymes in the human hepatocyte spheroids: The mRNA expression of 10 genes encoding drug-metabolizing enzymes was determined by qRT-PCR in the human hepatocyte spheroids cultured for 2 and 7 days. The expression levels of the enzymes were detected at lower levels (4.47% to 63.1%) than those of the enzymes in cryopreserved hepatocytes (100%) except for CYP1A2. Moreover, the mRNA levels in the hepatocytes cultured for 7 days increased compared with those cultured for 2 days except for CYP1A2 and CYP2E1 ( Table 3) .
Discussion
In this study, we evaluated the utility of 3D spheroid culture of human hepatocytes for drug metabolism in the stage of discovering metabolites. Because it is difficult to perform longterm culture of human hepatocytes in the conventional 2D culture system, sequential metabolism (Phase I ¼ Phase II) or multiple metabolic pathways could be hardly detected in several cases. 10, 11) For example, diclofenac is oxidized by CYP2C9 and is then conjugated by UGT2B7 in clinical studies. 12) However, diclofenac acyl glucuronide was not detected by the human hepatocyte suspensions at all. 13, 14) Meanwhile, diclofenac was metabolized to the corresponding acyl glucuronide (4A-hydroxy diclofenac acyl glucuronide) in this assay, suggesting the presence of sequential metabolism by CYP2C9 and UGT2B7. Additionally, Biotransformations of salbutamol and lamotrigine were investigated because their metabolites, which are not detected by incubation of cryopreserved hepatocyte suspensions, S-9 fraction and hepatic microsomes in humans, 14) are human specific. We investigated the metabolism of lamotrigine to lamotrigine-N-glucuronide, which was reported as a major metabolite by UGT1A4 and UGT2B7 [15] [16] [17] in several clinical studies, whereas this metabolite was hardly detected in rats or monkeys. 18) While its 2-N-methyl and N-oxide forms were not observed in this study, they may still exist below the detection limits, since these metabolites were found only in minor amounts in vivo. 19) In this study, salbutamol was converted to salbutamol 4-O-sulfate, which is also the main metabolite in clinical studies, 20) whereas the glucuronized form was found as the main metabolite in rodents. 21) In addition, a low response of salbutamol sulfate was observed. It is known that the major sulfotransferase (SULT) enzyme of salbutamol is SULT1A3 22) which is expressed predominantly in the human small intestine, not in the liver. 23) On the other hand, higher ion peak intensity was obtained by acetaminophen sulfate. Sulfation of acetaminophen was catalyzed by SULT1A1, SULT1A3/4, SULT1E1 and SULT2A1, which are highly expressed in the human liver. 24) Our results supported the findings of these previous reports. In addition, the difference in response between these sulfates may be caused by their different ionization efficiencies.
In this assay, acetaminophen was metabolized to glucuronide Table 2 . Metabolic profiling of compounds (10 µM) with the human hepatocyte spheroids cultured for 2 and 7 days after a spheroid formation period of 2 days
Studied compounds and in vivo major human metabolites
In vivo reference no.
Detection of metabolites in our system
Reference data Exposure period (days)
In All data are presented as the mean (n = 2). Data of metabolites are the peak area ratio to IS peak area, and remaining unchanged compounds are presented as % of 0 day. ND, not detected. CYP, cytochrome; DMPK, drug metabolism and pharmacokinetics; UGT, UDP-glucuronide transferase; SULT, sulfotransferase. The level of mRNA expression (%) was normalized to HPRT1 and was calculated relative to that of the cryopreserved hepatocytes (set to 100%) using the 2-¦¦ threshold cycles (Ct) method. 8) All data are presented as mean « S.E.M. (n = 3).
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and sulfate, and significant amounts of toxic NAPQI and its further metabolites were not observed. Acetaminophen is cleared primarily by glucuronidation and sulfation conjugation in therapeutic doses. However, at higher doses, conjugative pathways are overwhelmed and metabolism is increased by the alternate CYP oxidative pathway (CYP1A2 and CYP2E1). As a result, NAPQI and its further metabolites are formed. 25) This dose-dependent metabolism may result in no detection of the metabolites through NAPQI.
Most of the drug metabolisms are performed by Phase I and Phase II enzymes. In these assays, the observed activities of major metabolic enzymes were: CYP1A2 (propranolol), CYP2C9 (diclofenac), CYP2D6 (propranolol), CYP3A4 (midazolam), UGTs (acetaminophen, diclofenac, midazolam, propranolol and lamotrigine) and SULTs (acetaminophen and salbutamol). The metabolic assays using these tested compounds could not cover the major metabolism enzymes such as CYP2C19. Therefore, we investigated the mRNA assays to check expression of the enzymes: expressions of CYP2C19, CYP2E1 and GSTP1 were observed. Only the mRNA expression of CYP1A2 in the human hepatocyte spheroids was higher than that in the cryopreserved hepatocytes. It was reported that 7-ethoxyresorufin O-deethylase activity (mainly CYP1A1/2) in rat spheroid hepatocyte homogenates appeared to be maintained at a higher level than that in freshly isolated cells. 26) This implies that the expression of CYP1A2 increases in hepatocyte spheroid culture systems.
The process of developing drugs cannot always predict specific metabolites in humans. In addition, it is often not possible to obtain the reference standard of metabolites, especially at the screening stage. We used the ion peak areas of dextrorphan as an IS to determine the amounts and changes of metabolites in this study. Moreover, corresponding metabolites which were not commercially available were estimated using these calculated molecular weights and ion fragment patterns. This semi-quantitative method is convenient and useful for examining the chronological changes of the metabolites.
In conclusion, this study showed the efficacy of qualitatively predicting metabolites in humans. The benefits of this study are the detection of sequential metabolic reactions and human-specific metabolites that are difficult to identify by conventional assays. This assay is useful for the development of new drugs, offering high-throughput screening within one week. Further studies including toxicity evaluation using this methodology are needed.
